Petrof Elaine O
Department of Medicine, GIDRU and Division of Infectious Diseases, Queen's University, Kingston, ON Canada.
Antiinflamm Antiallergy Agents Med Chem. 2009 Sep 1;8(3):260-269. doi: 10.2174/187152309789151977.
Our intestinal microbiota serve many roles vital to the normal daily function of the human gastrointestinal tract. Many probiotics are derived from our intestinal bacteria, and have been shown to provide clinical benefit in a variety of gastrointestinal conditions. Current evidence indicates that probiotic effects are strain-specific, they do not act through the same mechanisms, and nor are all probiotics indicated for the same health conditions. However, they do share several common features in that they exert anti-inflammatory effects, they employ different strategies to antagonize competing microorganisms, and they induce cytoprotective changes in the host either through enhancement of barrier function, or through the upregulation of cytoprotective host proteins. In this review we focus on a few selected probiotics - a bacterial mixture (VSL#3), a Gram-negative probiotic (E. coli Nissle 1917), two Gram-positive probiotic bacteria (LGG, L. reuteri), and a yeast probiotic (S. boulardii) - for which sound clinical and mechanistic data is available. Safety of probiotic formulations is also discussed.
我们的肠道微生物群对人类胃肠道的正常日常功能起着许多至关重要的作用。许多益生菌来源于我们的肠道细菌,并且已被证明在多种胃肠道疾病中具有临床益处。目前的证据表明,益生菌的作用具有菌株特异性,它们并非通过相同的机制发挥作用,也并非所有益生菌都适用于相同的健康状况。然而,它们确实具有几个共同特征,即发挥抗炎作用、采用不同策略对抗竞争性微生物,并且它们通过增强屏障功能或上调宿主细胞保护蛋白在宿主中诱导细胞保护变化。在本综述中,我们重点关注几种选定的益生菌——一种细菌混合物(VSL#3)、一种革兰氏阴性益生菌(大肠杆菌Nissle 1917)、两种革兰氏阳性益生菌(LGG、罗伊氏乳杆菌)和一种酵母益生菌(布拉酵母菌)——针对这些益生菌有可靠的临床和机制数据。还讨论了益生菌制剂的安全性。